A patient has been taking lithium for 1 year, and the most recent lithium level is 0.9 mEq/L. Which statement about the laboratory result is correct?
The lithium level is too low
The lithium level is therapeutic
Lithium is not usually monitored with blood levels
The lithium level is too high
The Correct Answer is B
A. A lithium level of 0.9 mEq/L falls within the therapeutic range for lithium, so it is not too low.
B. A lithium level of 0.9 mEq/L is within the therapeutic range for lithium maintenance therapy, which typically ranges from 0.6 to 1.2 mEq/L. Therefore, it is considered therapeutic.
C. Lithium is commonly monitored with blood levels to ensure therapeutic efficacy and to prevent toxicity.
D. A lithium level of 0.9 mEq/L is not too high; it is within the therapeutic range.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is B
Explanation
A. Assessing the WBC count is not directly related to the administration of a nonselective adrenergic blocker. These medications primarily affect the cardiovascular system.
B. Assessing pulse and blood pressure is crucial before administering a nonselective adrenergic blocker. These medications can cause bradycardia and hypotension as side effects, so it's
important to ensure the client's baseline pulse and blood pressure are within acceptable ranges before giving the medication.
C. Assessing bowel sounds is not directly related to the administration of a nonselective adrenergic blocker. These medications primarily affect the cardiovascular system.
D. Assessing serum sodium and potassium levels is not directly related to the administration of a nonselective adrenergic blocker. These medications primarily affect the cardiovascular system.
Correct Answer is A
Explanation
A. Carbidopa prevents the breakdown of levodopa in the periphery, specifically in the gastrointestinal tract and peripheral tissues, allowing more levodopa to reach the brain and be converted to dopamine. This enhances the effectiveness of levodopa therapy in managing the symptoms of Parkinson's disease.
B. Carbidopa is not the biologic precursor of dopamine. It is a peripheral decarboxylase inhibitor that does not cross the blood-brain barrier.
C. Carbidopa does not directly allow for larger doses of levodopa to be given. However, by
inhibiting the peripheral breakdown of levodopa, it enhances the availability of levodopa to the central nervous system, potentially improving therapeutic efficacy.
D. While levodopa-carbidopa combination therapy may have fewer drug-food interactions compared to levodopa alone, the primary reason for combining these medications is to enhance the effectiveness of levodopa by preventing its peripheral breakdown.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.
